Stromal vascular fraction (SVF) therapy for treatment of various diseases: delivering safety of the first patented svf technique in indonesia

Moegni, K. Fernandi; Rosliana, Iis; Remelia, Melinda; Rosadi, Imam; Sobariah, Siti; Afini, Irsyah; Widyastuti, Tias

doi:10.1016/j.jcyt.2019.03.511

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Method 3 was invented by HayandraLab, as an improvement to the previous method, and was referred to as the H-Remedy method (patent application no. P00201603083) [28]. Lipoaspirates (about 15-600 mL) were digested by H-Remedy enzyme and incubated for 1 hour at 37°C, 300 rpm.…”

Section: Svf Processingmentioning

confidence: 99%

Safety of Technique and Procedure of Stromal Vascular Fraction Therapy: From Liposuction to Cell Administration

Karina¹,

Rosliana²,

Rosadi³

et al. 2020

Scientifica

View full text Add to dashboard Cite

Background. Stromal vascular fraction (SVF) therapy has been performed over the past six years to treat 421 patients by our group in five clinical centers. Autologous SVF, which is a substance containing stem cells, was isolated from lipoaspirate, mixed with platelet-rich plasma (PRP), and administered to patients with degenerative diseases, autoimmune diseases, trauma, aging, and other diseases with unknown etiology. This study aimed to determine the safety of SVF and PRP that were given through infusion, spinal, and intra-articular injection. Methods. The lipoaspirate was treated with a tissue-dissociating enzyme, and then, through centrifugation, SVF was isolated. In addition, blood was drawn from each patient, and PRP was isolated. Autologous PRP and SVF were administered to all subjects by intravenous (IV) injection. A minority group within the population received an additional spinal or intra-articular injection. The type of intervention was determined by each disease evaluation. The cell doses and adverse events for each patient were documented and analyzed. Results. Cell dose that was considered to be safe was less than 10 billion SVF cells in 250 cc of normal saline, for IV injection, and less than 1 billion SVF, for intra-articular and spinal injection. Adverse events were not severe and were treated successfully. Any observed adverse events were identified as a result of spinal or intra-articular injections and were not related to SVF or PRP. Conclusions. Our results showed that administration of high dose of SVF until 10 billion cells in a majority of 421 patients through infusion, spinal, and intra-articular injection was feasible without causing major adverse events and should be further investigated in well-designed phase I-II clinical trial to address the safety and efficacy of therapy.

show abstract

Section: Svf Processingmentioning

confidence: 99%

Safety of Technique and Procedure of Stromal Vascular Fraction Therapy: From Liposuction to Cell Administration

Karina¹,

Rosliana²,

Rosadi³

et al. 2020

Scientifica

View full text Add to dashboard Cite

show abstract

“…PRP has also been reported to be beneficial for ischemic stroke, osteoarthritis, and chronic ulcers. There have been no previous reports regarding the adverse event of PRP use in those cases or its combination with stromal vascular fraction (11,12,30,31,32,33). Our study showed that the intravenous administration of aaPRP in patients with various pathological conditions did not cause any adverse event.…”

Section: Discussionmentioning

confidence: 41%

Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma

Karina

Ekaputri

Biben

et al. 2021

JHSCI

View full text Add to dashboard Cite

Introduction: Autologous platelet-rich plasma (PRP) has been a growing trend in the field of medicine due to its broad range of application and is considered safe from bloodborne diseases. Furthermore, various studies have tried to optimize the use of autologous PRP through various preparation protocols, including PRP activation. However, most of the studies available have not evaluated the safety for intravenous delivery of PRP, especially autologous activated PRP (aaPRP). Therefore, this study aimed to evaluate the safety of intravenous delivery of aaPRP.Methods: Blood was drawn from each patient and aaPRP was isolated through calcium activation and light irradiation. Each aaPRP was administered intravenously to all patients. Adverse events were documented and analyzed.Results: Six hundred eleven patients participated in this study with a total of 4244 aaPRP therapies. Quality control of autologous aaPRP showed no platelets present after both calcium activation and light irradiation. No adverse events such as allergic reaction, infection, and coagulation problems were observed on all patients over the course of the study.Conclusion: Our results showed that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions.

show abstract

“…Fresh lipoaspirate was obtained from the abdominal fat of human donors. Tissue-dissociation enzyme (H-Remedy) was added to the lipoaspirate in 50 mL tubes 41 . The mixture was incubated for 1 hour in a 37 o C incubator.…”

Section: Msc Preparationmentioning

confidence: 99%

In vivo study of wound healing processes in Sprague-Dawley model using human mesenchymal stem cells and platelet-rich plasma

et al. 2021

View full text Add to dashboard Cite

Introduction: Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) have a potential role in improving wound healing processes. This experimental study aims to compare PRP and MSCs to promote the wound healing process in the animal burn wound model. Methods: PRP from venous blood and MSCs from lipoaspirates were isolated from six donors. Saline solution was used as control while PRP and MSCs as treatment groups were injected to second-degree burn wounds in the backs of 10 male Sprague-Dawley rats for each group. On day 7, 5 rats from each group were euthanized for analyses VEGF gene, which has a role in angiogenesis. At the end of the study (week 5), the remaining rats were euthanized for histological analysis. Results: The VEGF expression in MSCs and PRP groups was higher than the control group (not significant). The wound healing rate was also significantly faster until 21 days post-burn in the MSCs and PRP groups and getting slowly afterward. Histological analysis showed the burned skin at day 35 had displayed the best differentiation outcome in the MSCs group. In conclusion, human-derived MSCs and PRP do not accelerate epithelialization duration of rats burn wound model. However, they improved wound’s vascularization and cell differentiation. Conclusion: MSCs are superior to PRP in enhancing cell differentiation.

show abstract

Stromal vascular fraction (SVF) therapy for treatment of various diseases: delivering safety of the first patented svf technique in indonesia

Cited by 6 publications

References 0 publications

Safety of Technique and Procedure of Stromal Vascular Fraction Therapy: From Liposuction to Cell Administration

Safety of Technique and Procedure of Stromal Vascular Fraction Therapy: From Liposuction to Cell Administration

Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma

In vivo study of wound healing processes in Sprague-Dawley model using human mesenchymal stem cells and platelet-rich plasma

Contact Info

Product

Resources

About